These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 12168403)

  • 1. Variation in approach to ESBL Enterobacteriaceae among infection control practitioners: results of an Ontario-wide survey.
    Muller M; McGeer A
    Can Commun Dis Rep; 2002 Aug; 28(15):121-4. PubMed ID: 12168403
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical implications of extended spectrum beta-lactamase (ESBL) producing Klebsiella species and Escherichia coli on cefepime effectiveness.
    Kotapati S; Kuti JL; Nightingale CH; Nicolau DP
    J Infect; 2005 Oct; 51(3):211-7. PubMed ID: 16230218
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Control of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a children's hospital by changing antimicrobial agent usage policy.
    Lee J; Pai H; Kim YK; Kim NH; Eun BW; Kang HJ; Park KH; Choi EH; Shin HY; Kim EC; Lee HJ; Ahn HS
    J Antimicrob Chemother; 2007 Sep; 60(3):629-37. PubMed ID: 17599919
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of cefepime for the treatment of infections caused by extended spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli.
    Labombardi VJ; Rojtman A; Tran K
    Diagn Microbiol Infect Dis; 2006 Nov; 56(3):313-5. PubMed ID: 17084784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes evaluation of patients with ESBL- and non-ESBL-producing Escherichia coli and Klebsiella species as defined by CLSI reference methods: report from the SENTRY Antimicrobial Surveillance Program.
    Bhavnani SM; Ambrose PG; Craig WA; Dudley MN; Jones RN;
    Diagn Microbiol Infect Dis; 2006 Mar; 54(3):231-6. PubMed ID: 16423491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Prevalence of extended-spectrum beta-lactamases in nosocomial Escherichia coli and Klebsiella spp. strains isolated from blood cultures].
    Zarakolu P; Metan G; Hasçelik G; Akova M
    Mikrobiyol Bul; 2007 Oct; 41(4):579-84. PubMed ID: 18173077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extended-spectrum beta-lactamases and clinical outcomes: current data.
    Ramphal R; Ambrose PG
    Clin Infect Dis; 2006 Apr; 42 Suppl 4():S164-72. PubMed ID: 16544267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The prevalence of ESBL-producing E. coli and Klebsiella strains in the Copenhagen area of Denmark.
    Kjerulf A; Hansen DS; Sandvang D; Hansen F; Frimodt-Møller N
    APMIS; 2008 Feb; 116(2):118-24. PubMed ID: 18321362
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prior use of carbapenems may be a significant risk factor for extended-spectrum beta-lactamase-producing Escherichia coli or Klebsiella spp. in patients with bacteraemia.
    Martínez JA; Aguilar J; Almela M; Marco F; Soriano A; López F; Balasso V; Pozo L; Mensa J
    J Antimicrob Chemother; 2006 Nov; 58(5):1082-5. PubMed ID: 16950822
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extended spectrum b lactamases (ESBL) in clinical isolates of Klebsiella pneumoniae and Escherichia coli.
    Duttaroy B; Mehta S
    Indian J Pathol Microbiol; 2005 Jan; 48(1):45-8. PubMed ID: 16758790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High incidence of extended-spectrum beta-lactamases among outpatient clinical isolates of Escherichia coli: a phenotypic assessment of NCCLS guidelines and a commercial method.
    Sorlózano A; Gutiérrez J; Palanca M; Soto MJ; Piédrola G
    Diagn Microbiol Infect Dis; 2004 Oct; 50(2):131-4. PubMed ID: 15474323
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cefepime pharmacodynamics in patients with extended spectrum beta-lactamase (ESBL) and non-ESBL infections.
    Lee SY; Kuti JL; Nicolau DP
    J Infect; 2007 May; 54(5):463-8. PubMed ID: 17067681
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beta-lactam susceptibilities and prevalence of ESBL-producing isolates among more than 5000 European Enterobacteriaceae isolates.
    Nijssen S; Florijn A; Bonten MJ; Schmitz FJ; Verhoef J; Fluit AC
    Int J Antimicrob Agents; 2004 Dec; 24(6):585-91. PubMed ID: 15555882
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phenotypic confirmation of extended-spectrum B-lactamases (ESBL) in clinical isolates of Escherichia coli and Klebsiella pneumoniae at the San Juan Veterans Affairs Medical Center.
    Del Carmen Rodríguez M; Vera DE; Ramírez-Ronda CH; Saavedra S
    P R Health Sci J; 2004 Sep; 23(3):207-15. PubMed ID: 15631176
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in spanish hospitals (GEIH-BLEE Project 2002)].
    Hernández JR; Pascual A; Cantón R; Martínez-Martínez L;
    Enferm Infecc Microbiol Clin; 2003 Feb; 21(2):77-82. PubMed ID: 12586030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cefpodoxime screening of Escherichia coli and Klebsiella spp. by Vitek for detection of organisms producing extended-spectrum beta-lactamases.
    Gibb AP; Crichton M
    Diagn Microbiol Infect Dis; 2000 Dec; 38(4):255-7. PubMed ID: 11146252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overview of the epidemiological profile and laboratory detection of extended-spectrum beta-lactamases.
    Pfaller MA; Segreti J
    Clin Infect Dis; 2006 Apr; 42 Suppl 4():S153-63. PubMed ID: 16544266
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Antibiotic resistance rates of extended spectrum beta-lactamase producing Escherichia coli and Klebsiella spp. strains isolated from urinary tract infections in a private hospital].
    Akyar I
    Mikrobiyol Bul; 2008 Oct; 42(4):713-5. PubMed ID: 19149097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of risk factors for the acquisition of bloodstream infections with extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species in the intensive care unit; antibiotic management and clinical outcome.
    Cordery RJ; Roberts CH; Cooper SJ; Bellinghan G; Shetty N
    J Hosp Infect; 2008 Feb; 68(2):108-15. PubMed ID: 18063198
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk factors for increasing multidrug resistance among extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species.
    Hyle EP; Lipworth AD; Zaoutis TE; Nachamkin I; Fishman NO; Bilker WB; Mao X; Lautenbach E
    Clin Infect Dis; 2005 May; 40(9):1317-24. PubMed ID: 15825035
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.